Amicus Therapeutics, Inc. (NASDAQ:FOLD) hit a 52-week high on Friday, climbing to $10.85 before closing at $10.55, up 6.57%. Investment firm optimism and a bullish rating fueled the surge. Zacks Research issued a “strong buy” recommendation for FOLD, with a consensus price target of $15.90, implying a 50.7% potential upside. Third-quarter results showed a net income of $17.3 million compared to a net loss of $6.7 million last year. Net product sales rose by 20% to $169 million, with Galafold sales reaching $138 million and Pombiliti + Opfolda sales at $30.7 million. Analysts raised EPS targets for FOLD, anticipating better-than-expected earnings.

Read more at Yahoo Finance: Amicus Therapeutics (FOLD) Soars to 52-Week High on ‘Strong Buy’ Reco